Stocks
Invest in Stocks
Invest in stocks, ETFs, IPOs with fast orders. Track returns on your stock holdings and view real-time P&L on your positions.
Intraday
Monitor top intraday performers in real time
ETF Screener
Get the best of Mutual Funds and flexibility of Stocks
IPO
Track upcoming and ongoing IPOs
MTFs
Buy now, pay later
Stock Screener
Filter based on RSI, PE ratio and more
Stock Events
Dividends, bonus, buybacks and more
Demat Account
Begin your stock market journey
Share Market Today
Live news updates from stock market
F&O
Trade in Futures & Options
Trade in F&O using the terminal. View charts, indicators, track your orders , P&L and watchlists in a single space
Indices
Track markets across the globe
Terminal
Track charts, orders, positions, watchlists in one place
Option chain
Analyse chains, view payoffs, create baskets
Pledge
Get extra balance for trading
Commodities
Trade in Crude Oil, Gold, Silver and more
API trading
Set up and execute trades through our API
Mutual Funds
Invest in Mutual Funds
Invest in direct mutual funds at zero charges via lump sump investments or SIPs
Mutual Fund Houses
Know about AMCs, funds, fund managers
NFO’s
Track all active NFOs in one place
Mutual Funds by Groww
Mutual funds by Groww designed for your investment goals
Start SIP
Build long-term wealth through disciplined monthly investing.
Mutual Funds screener
Filter funds based on risk, fund size and more
Track Funds
Import funds and track all investments in a single place
Compare Funds
More
SIP calculator
Estimate returns on a SIP
Brokerage calculator
Estimate charges for your trade/investment
Margin calculator
Estimate balance needed to buy/sell a stock
SWP calculator
Returns on your systematic withdrawal plan
Pricing
Brokerage and charges on Groww
Blog
Credit
Loan against securities and Personal loan
Manage alerts
Active alerts for Lupin
Add new alert
LUPIN •
NSE
Lupin
₹2,110.00
-22.00 (1.03%)
1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Terminal
Create Stock SIP
Automate your investments in this
Overview
Technicals
News
Events
F&O
Business Standard •
15 hours ago
Lupin secures USFDA approval for Modafinil Tablets USP. No Business Standard journalist authored the provided news content.
ScoutQuest •
16 hours ago
Lupin gets US FDA approval for Modafinil 100 mg & 200 mg tablets. Modafinil, bioequivalent to Provigil, targets sleep disorders; Provigil's US sales were ~$70.7M (IQVIA MAT Jul 2026).
Livesquawk •
3 days ago
Kotak Institutional Equities maintains Add on Lupin; target price ₹2,525 citing margin support from lower investments. Future growth seen in Apixaban, gSpiriva, gDulera, biosimilars, and Ellipta despite Tolvaptan & Mirabegron sales decline.
BSE •
1 week ago
Lupin Ltd received an ESG Rating of 'Crisil ESG 69' and Core ESG Rating of 'Crisil Core ESG 65'. The ratings, by Crisil ESG Ratings, place Lupin in the 'Strong' category for FY26.
ScoutQuest •
1 week ago
Citi downgrades Lupin to Sell, cutting target price to ₹2,050 due to slowing US business. US sales may drop to $975M by FY29; Apixaban offers potential but carries execution risks.
ScoutQuest •
1 week ago
Lupin secures 180-day exclusivity for Ivacaftor in the US, with $20-30M annual sales potential. Bernstein retains outperform rating on Lupin, setting a target price of ₹2,707 per share.
ScoutQuest •
1 week ago
Lupin's generic cystic fibrosis drug cleared of infringing Vertex's patents in court ruling. Lupin's ivacaftor holds exclusive first-to-file rights, matching Vertex's drug equivalence.
ScoutQuest •
2 weeks ago
Lupin's VISUfarma secures exclusive EU license for YUVEZZI, an FDA-approved presbyopia therapy. The €75M deal includes regulatory, marketing, and distribution rights with strategic investment.
Livesquawk •
2 weeks ago
Lupin signs exclusive deal with Visus Therapeutics for YuveziTM in Europe. Total potential payments could reach €75M, including strategic funds and milestones.
ScoutQuest •
3 weeks ago
Lupin gets US FDA approval for Pitolisant tablets to treat daytime sleepiness.